A prescribed dose specifies the amount of drug administered, but it does not necessarily specify the exposure that a patient experiences. The distinction becomes clinically consequential when biological or treatment-related states change the processes connecting dose to systemic concentration. Inflammation can alter drug-metabolizing enzymes and transporters over time; kidney disease can modify active secretion as well as selected nonrenal pathways; hepatic dysfunction can affect metabolism, uptake, and extraction unevenly; and interacting drugs can shift functional metabolic phenotype away from that predicted by genotype. These mechanisms can converge on similar changes in exposure without being mechanistically interchangeable. The same measured concentration can therefore arise from different combinations of clearance, transport, adherence, interaction, disease, and phenotypic effects, while the same prescribed dose can produce different concentrations within the same patient as clinical state changes. This Perspective argues for separating the causal layers that generate exposure from the measurements used to observe it. Genotype, functional phenotype, organ function, interacting medicines, administered dose, measured concentration, and clinical response each answer different questions and should not be collapsed into a universal weighting scheme. Monitoring is most informative when the drug has a validated exposure target, clinically important consequences of misexposure, and a plausible mechanism that can be investigated or modified. The practical implication is conditional: prescribed dose becomes an unreliable proxy for biologically received exposure when a drug depends materially on pathways that are both clinically variable and dynamically altered in the patient being treated.
